Ulcerative colitis (UC) is a chronic, incurable disease characterized by periods of remission and relapse, with increasing global prevalence.
A comprehensive review involved healthcare professionals and patients to formulate clinical questions, retrieve evidence from various databases, and provide recommendations using the GRADE system.
For treatment, budesonide MMX is recommended for mild-to-moderate UC, while moderate-to-severe cases may utilize therapies like infliximab and adalimumab, with alternatives available if initial treatments fail.